MR

Maravai LifeSciences Holdings IncNASDAQ MRVI Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

2.331

Small

Exchange

XNAS - Nasdaq

MRVI Stock Analysis

MR

Uncovered

Maravai LifeSciences Holdings Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-15/100

Low score

Market cap $B

2.331

Dividend yield

Shares outstanding

131.78 B

Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 610 full-time employees. The company went IPO on 2020-11-20. The firm provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The firm's segments include Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The company also provides research products for labeling and detecting proteins in cells and tissue samples. Its products include CleanCap, messenger ribonucleic acid (mRNA) and oligonucleotide. The Biologics Safety Testing focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing spectrum. The firm provides ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets.

View Section: Eyestock Rating